![](https://i.imgur.com/CLvY2jA.png")
October 18, 2021
VLA2001 successfully met both co-primary endpoints
Superior neutralizing antibody titer levels compared to active comparator vaccine, AstraZeneca’s AZD1222 (ChAdOx1-S)
Neutralizing antibody seroconversion rate above 95%
VLA2001 induced broad T-cell responses with antigen-specific IFN-gamma-producing T-cells against the S, M and N proteins.
VLA2001 was well tolerated, demonstrating a statistically significant better tolerability profile compared to active comparator vaccine
Valneva has completed recruitment of 306 volunteers aged 56 years and older in New Zealand[1] into its VLA2001-304 trial and expects topline data in early 2022.
The Company is preparing for trials in children (5-12 years of age) and a Valneva sponsored booster trial to evaluate VLA2001’s booster performance for people in need of a booster.
https://valneva.com/press-release/valnev...e-vla2001/
VLA2001 successfully met both co-primary endpoints
Superior neutralizing antibody titer levels compared to active comparator vaccine, AstraZeneca’s AZD1222 (ChAdOx1-S)
Neutralizing antibody seroconversion rate above 95%
VLA2001 induced broad T-cell responses with antigen-specific IFN-gamma-producing T-cells against the S, M and N proteins.
VLA2001 was well tolerated, demonstrating a statistically significant better tolerability profile compared to active comparator vaccine
Valneva has completed recruitment of 306 volunteers aged 56 years and older in New Zealand[1] into its VLA2001-304 trial and expects topline data in early 2022.
The Company is preparing for trials in children (5-12 years of age) and a Valneva sponsored booster trial to evaluate VLA2001’s booster performance for people in need of a booster.
https://valneva.com/press-release/valnev...e-vla2001/
